Education
About Us
Working with TipRanks
Follow Us
Delta-Fly Pharma, Inc. (JP:4598)
:4598
RESEARCH TOOLSreports
4598 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥403.00 - ¥765.00
Previous CloseN/A
Volume237.90K
Average Volume (3M)391.92K
Market Cap
¥6.95B
Enterprise Value¥2.57B
Total Cash (Recent Filing)¥738.00M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.65
Shares Outstanding10,925,000
10 Day Avg. Volume409,850
30 Day Avg. Volume391,920
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-2.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥403.00 and its highest was ¥765.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥6.95B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is Aug 08, 2025 which is in 52 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on May 15, 2025. The company reported -¥41.65 earnings per share for the quarter, missing the consensus estimate of N/A by -¥41.65.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 10,925,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥41.65 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.706%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Technical Analysis
OncoTherapy Science
―
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
BrightPath Biotherapeutics Co.Ltd.
―
Kringle Pharma, Inc.
―